Author of

• 15382

  +

  P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Biology, Pathology, and Molecular Testing
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15515

    +

    P3.04-133 - ADAM9 and EGFR Correlated With Lymph Node Metastasis Predicts Worse Prognosis in Surgically Resected Non-Small Cell Lung Cancer (ID 1379)

    09:30 - 09:30  |  Author(s): N. Chen
    • Abstract

    Background:
    Recently we first reported that a disintegrin and metalloproteinase-9 (ADAM9) was highly expressed in resected non-small cell lung cancer (NSCLC), correlated with lymph node metastasis, shorterned survival time. ADAM9 has been known of being able to enhance the expression of epidermal growth factor receptor (EGFR) pathway, here, we investigate the expression of EGFR in surgically resected NSCLC, to elucidate the relationship between EGFR expression and lymph node metastasis, prognosis, and further evaluate the consistence of ADAM9 expression and EGFR expression, and their significance as novel biomarkers in molecular staging, predicting the prognosis for surgically resected NSCLC.
    
    Methods:
    One hundred and six cases of completely resected stage Ⅰ, Ⅱ and Ⅲ NSCLC with mediastinal N2 lymph nodes dissected were immunohistochemically analyzed for EGFR and ADAM9 protein expression. Survival analysis was conducted to assess the significance of EGFR and ADAM9 expression and the relationship with other clinicopathological characteristics.
    
    Results:
    Of the 106 NSCLC, 49 were stage Ⅰ, 16 stage Ⅱ and 41 stage Ⅲ; 60.4% was found with EGFR protein highly expressed (EGFR+), significantly higher when compared with normal control lung tissues (P=0.000). The EGFR+ rate in stage Ⅱ and Ⅲ NSCLC was 73.7%, significantly higher than 44.9% in stage Ⅰ (P=0.003). Stratified, EGFR+ rates in N1 and N2 cases was 72.0%, significantly higher than 50.0% in N0 NSCLC (P=0.021); the difference between EGFR+ rates in T factor groups was not statistically significant (P>0.05). The overall 5-year survival rate was 55.7% for this group of 106 completely resected NSCLC. The 5-year survival rate in EGFR low expression (EGFR-) group (42 cases) was 74.9%, however, the 5-year survival rate was sharply decreased to 43.2% in EGFR+ group (64 cases) (P=0.001). For ADAM9, the ADAM9+ rates in stage Ⅱ and Ⅲ NSCLC was significantly higher than in stage Ⅰ (P=0.013). Stratified, ADAM9+ rates in N1 and N2 cases was significantly higher than in N0 NSCLC (P=0.040). The difference between ADAM9+ rates in T factor groups was not statistically significant (P>0.05). The 5-year survival rate in ADAM9+ group was statistically lower than in ADAM9- group (P=0.040). EGFR expression was revealed correlated positively and significantly with ADAM9 expression in this group of surgically resected NSCLC (Pearson r=0.275, P=0.004).
    
    Conclusion:
    This report for the first time revealed the relationship of expression of EGFR and ADAM9 protein in human lung cancer tissues. EGFR and ADAM9 are highly expressed in human resected NSCLC, correlated with lymph node metastasis and pTNM stage; highly expressed EGFR and ADAM9 predicts worse prognosis, suggesting that EGFR and ADAM9 are useful molecular staging biomarkers, and prognostic biomarkers for NSCLC. EGFR and ADAM9 may also become useful predictive biomarkers helping decide if postoperative chemo-radiation therapy should be selected or not. (This study was partly supported by grants from the Education Department of Liaoning Province, China, No. 20060991; the Nature Science Foundation of Liaoning Province, China, No.20102285; and the Fund for Scientific Research of The First Hospital of China Medical University, No.FSFH1210).